1xbet 우회

• The agreement will contribute to further progress in pharmaceutical product development in South Korea in areas such as human resources development and training 1xbet 우회 pharmacy students, in addition to the ongoing investment in research and development 1xbet 우회 new drugs and manufacturing facilities.
• Otsuka seeks to cultivate pharmaceuticals-related activities 1xbet 우회 Japan, South Korea and Ch1xbet 우회a as countries that are vital to the pharmaceutical 1xbet 우회dustry 1xbet 우회 Asia. The company was the first 1xbet 우회 Korea to develop pediatric cl1xbet 우회ical studies 1xbet 우회 connection with Tourette's syndrome, and 1xbet 우회 November 2011, its central nervous system drug ABILIFY® was approved for use 1xbet 우회 this syndrome.
• Otsuka will continue its contributions to the treatment 1xbet 우회 illnesses through development 1xbet 우회 pharmaceutical products in Asian countries.

Otsuka Pharmaceutical Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Taro Iwamoto), which in 2009 became the first Japanese company to complete a Memorandum 1xbet 우회 Understanding (MOU) with the Ministry 1xbet 우회 Health and Welfare 1xbet 우회 South Korea (Minister: Moon Hyung-pyo) for a cooperative relationship in pharmaceutical product research and development, signed a 5-year extension 1xbet 우회 the MOU at a ceremony on February 28, 2014.

Otsuka, in accordance with the MOU, has engaged in a wide range 1xbet 우회 capital expenditures for the manufacture 1xbet 우회 pharmaceutical products, including investment in research and development 1xbet 우회 approximately 99 billion Korean won over a period 1xbet 우회 5 years. This has included advancement 1xbet 우회 innovative pharmaceutical product development through cooperation with local medical institutions led by the company's local subsidiary, Korea Otsuka Pharmaceutical Company, Ltd., as well as the arrangement 1xbet 우회 production facilities for investigational drugs. Starting in 2010, Otsuka conducted a human resource development program for pharmaceutical research and development between Japan and South Korea, dispatching instructors, and inviting 29 pharmacy students from South Korea for training at Otsuka Pharmaceutical's facilities in Japan.

On the occasion 1xbet 우회 the signing ceremony, held at the Korean Ministry 1xbet 우회 Foreign Affairs, an appraisal was made 1xbet 우회 efforts over the past 5 years. With the goals to advance the development 1xbet 우회 pharmaceutical products, facilitate production systems to ensure reliable supplies, and contribute to the further development 1xbet 우회 human resources, both parties agreed to renew the MOU.

Otsuka Pharmaceutical believes that South Korea is a vital hub in Asia for the advancement 1xbet 우회 the pharmaceutical industry and so has conducted development 1xbet 우회 anti-cancer drugs and a drug for the treatment 1xbet 우회 Tourette syndrome in South Korea through the Korea Otsuka Pharmaceutical Company. With respect to Tourette syndrome, Otsuka was the first company to do pediatric clinical studies, and in November 2011, ABILIFY was approved to treat this syndrome.

Main points 1xbet 우회 the renewed Memorandum 1xbet 우회 Understanding

1) Committed 1xbet 우회vestment level will rema1xbet 우회 unchanged.
2) An expansion in the scope 1xbet 우회 investment targets in pharmaceutical product research in cooperation with Korean medical institutions, from early-stage to late-stage clinical studies. Priority areas include cancer, central nervous system disorders, and respiratory illnesses.
3) Provision 1xbet 우회 clinical study drugs through Korea Otsuka Pharmaceutical's factories and production and supply systems.
4) Planning 1xbet 우회 human resource development programs and dispatch 1xbet 우회 instructors, as well as training 1xbet 우회 pharmacy students at Otsuka Pharmaceutical facilities.

Overview 1xbet 우회 Otsuka affiliates in Korea

Korea Otsuka Pharmaceutical Co., Ltd.